KIT and CK2 signalling were evaluated by immunoblots in GIST-T1, GIST882, GIST430/654 and GIST48 after 6 h of treatment with imatinib and/or CX4945 in serum-free conditions (Fig. 3a). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.